The levels of selected mRNA and miRNA observed on microarray studies were validated by using a SYBR-based quantitative RT-PCR method [ 25].
To confirm differential gene expression levels in the three breast cancer subtypes, Her2+, ER + and TNBC, we selected 6 genes (ITGA3, ITGA5, OXTR, WNT5B, BCAR1, FZD1) with significantly different levels of expression based on our microarray studies and validated their expression levels by qRT-PCR.
miRNAs identified in the microarray study were validated using individual real-time qRT-PCR assays.
None of the microarray studies identified have validated their results using RT-PCR.
Taken together, these studies validate the microarray profiles, confirm the relative cascades of gene expression, demonstrate their absolute dependence on intact NF-κB signaling, and indicate the Early and Late members show similar binding affinities for the transactivating NF-κB family subunits.
Analysis of two prostate microarray studies (GSE1065 and GSE8402) validated the findings.
However, the increase in the expression of LOX and other matrix components observed in these microarray studies was not subsequently validated using other techniques (Henegar et al., 2008).
The expression levels of the eight miRNAs identified in the microarray study were initially validated using individual real-time qRT-PCR assays and a new set of twelve AAA and seven control aortic tissue samples (Table 1 and Additional file 1: Table S1).
The present study aims were to validate microarray studies that demonstrate TFF3 regulation by oestrogen and its association with oestrogen receptors in breast cancer, to evaluate TFF3 as a biomarker of endocrine response, and to investigate TFF3 function.
The data reported here summarize trends the expression of selected microRNA (in bold) that have been noted in microarray studies and that were independently validated (by real-time RT-PCR).
